Ann: Quarterly Activity Report and Appendix 4C, page-14

I suspect the general market is scratching its head about why a biotech company that doesn’t have a single patient enrolled in any trial can be sitting on a market cap around $300m !

The general market, of course, doesn’t have RAC management's ,Mason's and the RAC fan club's deep knowledge of Bisantrene's super powers…instead, the general market is asking, “how can a biotech company with not a single patient enrolled in any trial be even listed on the ASX, let alone command a market cap of $300m?”

I am eagerly awaiting that “first-patient in” announcement… it seems almost incredible that I probably will have to wait until around the end of the year for it to happen!